Grant Government contract announced Jun 25, 2026. Source: SEC filing. source ↗
Trial start Phase 1: A Trial of a Norovirus G1.1 and G2.4 Vaccine Administered Orally to Healthy Participants Aged ≥ 18 Years and ≤ 80 Years Old source ↗
Trial start Phase 2: A Study to Evaluate VXA-CoV2-3.3 COVID-19 Vaccine Against Currently Approved/Authorized mRNA COVID-19 Injectable Booster Vaccine in Adults Previously Immunized Against COVID-19 Infection source ↗
Trial start Phase 1: A Study to Evaluate Vaxart's Oral Bivalent GI.1/GII.4 Norovirus Vaccine in Healthy Lactating Females and Their Nursing Infants source ↗
Trial start Phase 2: A Study to Determine the Safety and Immunogenicity of Bivalent GI.1 and GII.4 Vaccines in Healthy Volunteers source ↗
Trial start 1: A Phase 1, Open-label, Safety and Immunogenicity Study of an Oral Multi-dose Administration Regimen With an Adenoviral-vector Based Tablet Norovirus Vaccine (VXA-G1.1-NN) Administered to Healthy Ad source ↗
Trial start Phase 1/Phase 2: Norovirus Challenge Study source ↗
Trial start Phase 2: A Ph 2 Trial With an Oral Tableted COVID-19 Vaccine source ↗
Trial start Phase 1/Phase 2: Immunogenicity & Safety Study of Adenovirus Type 5 (AD5) Based Oral Norovirus Vaccines source ↗
Trial start Phase 1: Ph 1b: Safety & Immunogenicity of Ad5 Based Oral Norovirus Vaccine source ↗
Trial start Phase 1: Safety and Immunogenicity Trial of an Oral SARS-CoV-2 Vaccine (VXA-CoV2-1) for Prevention of COVID-19 in Healthy Adults and Boost (VXA-CoV2-1.1-S) at 1 Year Post Initial Vaccination in Subset source ↗
Trial start Phase 1: Safety & Immunogenicity Study of Ad5 Based Oral Norovirus Vaccines source ↗
Trial start Phase 1: Dose-Optimization Trial of VXA-G1.1-NN in Healthy Volunteers source ↗
Trial start Phase 1: Pharmacodynamic Open-Label Trial With VXA-A1.1 Oral H1 Vaccine in Healthy Adults source ↗
Trial start 2: A Phase 2 Influenza A Challenge Study Following Oral Administration of an H1N1 HA Ad-Vector Seasonal Flu Vaccine source ↗
Trial start 1: Phase 1 Placebo-controlled, Randomized Trial of an Adenoviral-vector Based Norovirus Vaccine source ↗
Trial start Phase 1: Dose-Ranging Trial of Safety & Immunogenicity of an Oral Adenoviral-Vector Based RSV Vaccine (VXA-RSV-f) source ↗
Trial start Phase 2: A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Twice Daily Topical Applications of AP611074 5% Gel for up to 16 Weeks in Condyloma Patients source ↗
Trial start Phase 1: Assessment of an Oral Influenza B Vaccine Tablet (VXA-BYW.10) Following Single Dose Administration in Healthy Adults source ↗
Trial start Phase 1: Immunogenicity of Seasonal Influenza by Delivery Directly to Ileum source ↗
Trial start Phase 1: Safety Study of an Oral Vaccine to Prevent Seasonal Influenza source ↗
Trial start Phase 1: Immunogenicity of ND1.1 by Delivery Directly to the Ileum source ↗
Trial start Phase 1: Safety Study of an Oral Vaccine to Prevent Avian Influenza source ↗
Upcoming milestones
2027-05 (ESTIMATED) · Phase 2 · A Study to Evaluate VXA-CoV2-3.3 COVID-19 Vaccine Against Currently Approved/Authorized mRNA COVID-19 Injectable Booster Vaccine in Adults Previously Immunized Against COVID-19 Infection · NCT06672055
Estimated primary completion per ClinicalTrials.gov. Dates move.
Funding
Last 2 years.
Government contract announced Jun 25, 2026. Source: SEC filing. source ↗
A Study to Evaluate VXA-CoV2-3.3 COVID-19 Vaccine Against Currently Approved/Authorized mRNA COVID-19 Injectable Booster Vaccine in Adults Previously Immunized Against COVID-19 Infection
A Phase 1, Open-label, Safety and Immunogenicity Study of an Oral Multi-dose Administration Regimen With an Adenoviral-vector Based Tablet Norovirus Vaccine (VXA-G1.1-NN) Administered to Healthy Adult Volunteers
Safety and Immunogenicity Trial of an Oral SARS-CoV-2 Vaccine (VXA-CoV2-1) for Prevention of COVID-19 in Healthy Adults and Boost (VXA-CoV2-1.1-S) at 1 Year Post Initial Vaccination in Subset of Subjects
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Twice Daily Topical Applications of AP611074 5% Gel for up to 16 Weeks in Condyloma Patients
Safety Study of an Oral Vaccine to Prevent Avian Influenza
Phase 1
Completed
2011-04
2012-08 (actual)
NIH awards 9
Annual award amounts. Total $5.0M.
NIH award 5R44AI074216-05 FY2011: $975,540 awarded for that fiscal year; activity R44 (SBIR); PI TUCKER, SEAN N; recipient as written: VAXART, INC., South San Francisco, CA. Enhanced Oral Vaccine Delivery Vehicle source ↗
NIH award 5R44AI074216-04 FY2010: $850,927 awarded for that fiscal year; activity R44 (SBIR); PI TUCKER, SEAN N; recipient as written: VAXART, INC., South San Francisco, CA. Enhanced Oral Vaccine Delivery Vehicle source ↗
NIH award 5U01AI078205-02 FY2010: $631,471 awarded for that fiscal year; activity U01 (OTHER_NIH); PI TUCKER, SEAN N; recipient as written: VAXART, INC., South San Francisco, CA. Mucosal Vector with TLR3 agonist for source ↗
NIH award 1U01AI078205-01 FY2009: $615,325 awarded for that fiscal year; activity U01 (OTHER_NIH); PI TUCKER, SEAN N; recipient as written: VAXART, INC., South San Francisco, CA. Mucosal Vector with TLR3 agonist for source ↗
NIH award 2R44AI074216-03A1 FY2009: $953,135 awarded for that fiscal year; activity R44 (SBIR); PI TUCKER, SEAN N; recipient as written: VAXART, INC., South San Francisco, CA. Enhanced Oral Vaccine Delivery Vehicle source ↗
NIH award 5R43AI077254-02 FY2009: $120,993 awarded for that fiscal year; activity R43 (SBIR); PI TUCKER, SEAN N; recipient as written: VAXART, INC., South San Francisco, CA. Recombinant Adenoviral Vector with Encoded source ↗
NIH award 5R43AI074216-02 FY2008: $300,000 awarded for that fiscal year; activity R43 (SBIR); PI TUCKER, SEAN N; recipient as written: VAXART, INC., South San Francisco, CA. Enhanced Oral Vaccine Delivery Vehicle source ↗
NIH award 1R43AI077254-01 FY2008: $219,512 awarded for that fiscal year; activity R43 (SBIR); PI TUCKER, SEAN N; recipient as written: VAXART, INC., South San Francisco, CA. Recombinant Adenoviral Vector with Encoded source ↗
NIH award 1R43AI074216-01A1 FY2007: $299,082 awarded for that fiscal year; activity R43 (SBIR); PI TUCKER, SEAN N; recipient as written: VAXART, INC., SAN FRANCISCO, CA. Enhanced Oral Vaccine Delivery Vehicle source ↗
Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.
